Xtandi enzalutamide: Phase III ongoing

Medivation and Astellas said an interim analysis is planned this year for the double-blind, placebo-controlled, international Phase III PREVAIL trial comparing once-daily 160 mg oral Xtandi plus standard of care (SOC) vs. SOC alone in 1,717 patients who have failed androgen deprivation therapy. The partners said the number of radiographic PFS events has been exceeded and that the primary PFS analysis will also occur at the time of the interim analysis. PREVAIL completed enrollment last May (see BioCentury, June 11, 2012). ...